Collaboration with Yuhan Corporation on NASH

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan CorporationBoehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosisCollaboration aims to develop first-in-class dual agonist (GLP1R/FGF21R agonist) for NASHYuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties

Source: Boehringer Ingelheim Corporate News - July 1, 2019 Category: Research Source Type: news